SCHEMBL19486480

SCHEMBL19486480

CCN1CCN(c2ccc(-c3cc4c(N5CCN(C(=O)C6CCCCC6)CC5)ccnn4c3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.47
MAPT P10636 4/20 0.44
TDP1 Q9NUW8 2/20 0.44
TSHR P16473 2/20 0.44
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.41
NAMPT P43490 1/20 0.40
RUVBL1 Q9Y265 1/20 0.40
POLB P06746 1/20 0.39
RET P07949 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19481808 0.97 MAPT (0.45) HSD11B1MAPTTDP1TSHRKMT2A
SCHEMBL19481748 0.95 KMT2A (0.44) HSD11B1MAPTTDP1KMT2AMEN1
SCHEMBL19481958 0.92 KMT2A (0.41) HSD11B1MAPTTDP1KMT2AMEN1
SCHEMBL19481880 0.90 KMT2A (0.39) MAPTTDP1TSHRKMT2AMEN1
SCHEMBL19481873 0.90 KMT2A (0.39) MAPTTDP1TSHRKMT2AMEN1
SCHEMBL19486471 0.89 MAPK8 (0.41) HSD11B1MAPTTDP1KMT2AMEN1
SCHEMBL19481966 0.89 MAPK8 (0.41) HSD11B1MAPTTDP1KMT2AMEN1
SCHEMBL19491023 0.88 MEN1 (0.40) MAPTKMT2AMEN1MAPK1RET
SCHEMBL19482433 0.88 TDP1 (0.46) MAPTTDP1TSHRKMT2AMEN1
SCHEMBL19481942 0.88 MAPT (0.40) MAPTTDP1TSHRKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 US disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 HSD11B1 2291/4885MAPT 3886/4885TDP1 2048/4885
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 HSD11B1 1585/4885MAPT 3683/4885TDP1 2701/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 HSD11B1 2291/4885MAPT 3886/4885TDP1 2048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.